{"id":"apx3330","safety":{"commonSideEffects":[{"rate":"10%","effect":"Increased intraocular pressure"},{"rate":"5%","effect":"Cataract"},{"rate":"5%","effect":"Eye pain"}]},"_chembl":{"chemblId":"CHEMBL578390","moleculeType":"Small molecule","molecularWeight":"378.47"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"APX3330 is a small molecule inhibitor of TGFBR2, which is involved in the TGF-β signaling pathway. This inhibition is thought to reduce fibrosis and inflammation in the eye.","oneSentence":"Inhibits the enzyme TGFBR2","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:28:51.188Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of diabetic retinopathy"}]},"trialDetails":[{"nctId":"NCT04692688","phase":"PHASE2","title":"Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy","status":"COMPLETED","sponsor":"Ocuphire Pharma, Inc.","startDate":"2021-04-08","conditions":"Diabetic Retinopathy, Diabetic Macular Edema, NPDR - Non Proliferative Diabetic Retinopathy","enrollment":103},{"nctId":"NCT03375086","phase":"PHASE1","title":"A Study of APX3330 in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Apexian Pharmaceuticals, Inc.","startDate":"2018-01-30","conditions":"Cancer","enrollment":19}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["E3330"],"phase":"phase_2","status":"active","brandName":"APX3330","genericName":"APX3330","companyName":"Ocuphire Pharma, Inc.","companyId":"ocuphire-pharma-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Inhibits the enzyme TGFBR2 Used for Treatment of diabetic retinopathy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}